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sive disease), response (with/without complete response), and adverse events (with/
without grade ≥ 3 AEs). Generalized estimating equation (GEE) models provided 
direct estimation of HSUVs, controlling for confounders. Mapped HSUVs were com-
pared with published HSUVs in RRMM to assess reliability. Results: The algorithm 
that included the EORTC QLQ-C30 and EORTC QLQ-MY20 produced reliable HSUV 
estimates providing greater differentiation between health states. The overall mean 
estimate for progression-free disease (PFD) was 0.733. PFD with response was 0.744 
and PFD with no response was 0.704. The difference between scores with/without 
grade 3 AEs suggested a utility loss of 0.029; the AE decrement was greater (0.034) 
when using a proxy measure of patients who were off treatment but not in pro-
gressive disease. Similar patterns across the health states were seen by treatment 
regimen throughout the duration of the trial. GEE results were consistent with 
descriptive summaries. ConClusions: Mapped EQ-5D scores showed a consistent 
trend across health states, with higher HSUVs for pre-progression than progressive 
disease, for response versus no response, and without AEs versus with AEs. HSUVs 
were dependent on disease state and treatment regimen. The algorithm including 
both the EORTC QLQ-C30 and EORTC QLQ-MY20 provided reliable HSUV estimates 
in this RRMM population.
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objeCtives: Mapping a disease specific measure of quality of life to a generic 
instrument is one available technique to obtain utility values for cost-effectiveness 
studies. Based on a literature review on mapping techniques in oncology, we found 
that three models performed best: an OLS (Ordinary Least Square) regression 
with spline transformation, a multinomial logistic regression and a beta binomial 
regression. Our objective was to compare those three methods and a standard 
OLS regression for the mapping of the EORTC QLQ-C30 questionnaire to EQ-5D 
in patients with non-small cell lung cancer (NSCLC). Methods: We used data 
from a cross-sectional study performed in a Canadian cancer centre where QLQ-
C30 and EQ-5D questionnaires were completed on a single visit by 172 patients. 
We compared the results obtained with the OLS regression and the other meth-
ods according to the goodness-of-fit of the model (adjusted-R2) and the predic-
tive ability (Mean Absolute Deviation or MAE and the Root Mean Square Error or 
RMSE). Analyses were replicated for 3 utility tariffs (US, UK and France). Results: 
We found a mean observed utility of 0.6768 in our sample (standard deviation = 
0.2848). The OLS regression with spline dominated all other methods, whichever 
tariff was used. With the UK tariff, the adjusted R2, MAE and RMSE were 0.6507, 
0.1120 and 0.1683 respectively for the OLS with spline, vs. 0.5796, 0.1301 and 0.1847 
respectively for the standard OLS. Better goodness-of-fit and predictive ability 
were obtained with the US tariff (adjusted R2 of 0.6900, MAE of 0.0694 and RMSE 
of 0.1114 for OLS with splne). ConClusions: Using OLS with spline provides a 
notable improvement in goodness-of-fit and a better predictive ability compared 
to other regressions. Further analysis will be performed to observe the robustness 
of those results on other datasets.
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objeCtives: This systematic literature review (SLR) aimed to identify health 
related quality of life (HRQoL) and health utility parameters among newly diag-
nosed multiple myeloma (MM) patients. Methods: Systematic searches were 
conducted in literature databases including Embase® and MEDLINE® from Januray 
2005 to June 2015. English language studies, regardless of design and interven-
tion were included. Each study was reviewed by two independent reviewers; any 
disagreements were resolved by a third reviewer. Results: Out of the 680 cita-
tions retrieved from literature databases, 12 were included in the review. The 
included studies were observational (n= 6), randomised controlled trials (n= 5), or 
cost-effectiveness analysis (n= 1). Of 12 included studies, seven were conducted in 
US, three in Europe, and one each in Europe/US and Europe/other countries. Most 
commonly reported HRQoL scales were EORTC OLQ-C30, QLQ-MY20, and FACT-MM; 
while, health utility was estimted by EQ-5D. The HRQoL was significantly impaired 
in patients with MM compared to normative patients in terms of EORTC QLQ-C30 
(p< 0.01); with QoL, dyspnoea, physical functioning, role functioning, and social 
functoning subscales being the most affected. Further, disease progression was 
associated with a worsening in HRQOL scores (p< 0.001). Impaired HRQoL was 
reported in patients with MM because of disease related symptoms like bone pain 
and fatigue. Mean pain scores worsened with more severe disease stage (p< 0.05). 
Impaired HRQoL due to higher fatigue and pain scores was associated with shorter 
overall survival. Males had better HRQoL scores compared to females (p= 0.04) and 
blacks had better HRQoL scores compared to non-blacks (p= 0.03). Additionally, 
impaired health-related utility values were reported in patients with MM as sug-
ested by a mean EQ-5D score of less than 0.5. ConClusions: Disease severity, 
gender, and race are few of the parameters that are associated with deterioration 
of HRQoL in patients with newly-diagnosed MM. Delaying disease progression 
could possibly help to improve HRQoL.
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the 95% confidence interval, showed a predominance for the attribute “overall sur-
vival” (coef: 1,568). The attributes “response to treatment” (coef: 0,617) and “stabi-
lization of tumor growth” (coef: 0,547) followed. However, the side effects “nausea/
vomiting” and “diarrhea” are considered of relatively equal importance (coef: 0,544 
/ 0,413). The analysis of possible subgroup differences using latent class analysis 
revealed three preference patterns. The adverse event “occurrence of abdominal 
pain” had a significant effect in just one class. ConClusions: The results thus 
provide evidence about how much influence a treatment capacity has on thera-
peutic decision. The preference measurement showed that “overall survival” has 
the strongest influence on the therapeutic decision. The preference analysis also 
made it clear that the participants weight the outcome attributes higher than the 
side effects. Thus it becomes clear that a mono-criterial decision would not fully 
reflect the patient benefits.
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objeCtives: To evaluate the difference in quality of life of hormone-sensitive 
(HSPC) and castrate-resistant (CRPC) prostate cancer patients in the US as meas-
ure by EuroQol-5D and FACT-P. Methods: Data were extracted from the Adelphi 
Real World Prostate Cancer Disease-Specific Programme© (DSP), a cross-sectional 
survey of 137 urologists and oncologists and their prostate cancer patients, con-
ducted in the US between February and May 2014. Physicians completed detailed 
record forms for the next 12 consulting patients receiving prescribed drug therapy 
for prostate cancer. Each patient was invited to complete a questionnaire which 
included the EQ-5D and FACT-P tools. The scores were compared between HSPC 
and CRPC patients using t-tests or Mann-Whitney tests. Results: The physicians 
provided records for 1,330 prostate cancer patients of which 604 were categorized 
as HSPC and 492 as CRPC. Among the HSPC patients, 203 completed the EQ-5D, the 
mean utility index score was 0.84, which was significantly better (p= 0.0004) when 
compared to 0.78 (n= 182) for CRPC patients. Similarly, the quality of life as meas-
ured by FACT-P was generally better among HSPC patients than CRPC patients in 
a number of domains, including physical well-being [21.0 (n= 203) vs 19.6 (n= 187), 
p= 0.0119] and emotional well-being [15.8 (n= 203) vs 14.7 (n= 186), p= 0.0217], but 
not the social well-being [18.6 (n= 206) vs 19.7 (n= 187), p= 0.0382] and there was no 
statistical difference in the FACT-P score [102.1 (n= 198) vs 98.9 (n= 182). In HSPC 
patients, worse QoL was seen with patients with a worse ECOG performance sta-
tus. ConClusions: The development and subsequent progression of prostate 
cancer to CRPC represents a significant additional humanistic burden for patients, 
as indicated by the significant HSPC vs CRPC difference captured by EQ5D. Multiple 
domains particularly physical and emotional may contribute to the deterioration 
of quality of life during disease progression.
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objeCtives: To derive EORTC-8D health state utility values from patient-reported 
EORTC QLQ-C30 scores from the ASPIRE trial. ASPIRE is a randomized, open-label, 
phase 3 trial, which evaluated the efficacy and safety of carfilzomib with lenalido-
mide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in 
relapsed multiple myeloma. Methods: EORTC-8D is a condition-specific preference 
based measure with eight dimensions from EORTC QLQ-C30: Physical functioning, 
role functioning, pain, emotional functioning, social functioning, fatigue and sleep 
disturbance, nausea and constipation and diarrhea. Episodic random utility model 
(ERUM) was used to derive the EORTC-8D health state utility values from EORTC QLQ-
C30 at baseline for the overall ASPIRE trial population and trial arms using the UK 
tariff. Results: Estimated EORTC-8D utility values ranged from 0.291 to 1.0 which 
is congruent with the expected range of health utility values based on a UK tariff. 
The estimated baseline (cycle 1) utility values [mean (SD)] were 0.7834 (0.1289) for 
the overall population (n= 734), 0.7851(0.1266) and 0.7816 (0.1314) for the KRd (n= 370) 
and Rd (n= 364) treatment arms, respectively. ConClusions: The EORTC-8D enables 
QALYs to be directly estimated using the EORTC QLQ-C30 as an alternative to generic 
measures which may not be as sensitive to quality of life changes in cancer. This 
measure will provide appropriate and useful information for cost per QALY analysis.
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objeCtives: Health state utility values (HSUVs) are required for cost-effectiveness 
analysis of new medicines. Health-related quality-of-life data collected from the 
widely accepted EQ-5D are often not available and data from other instruments need 
to be mapped using algorithms. The objective of this study was to map HSUVs using 
data from a clinical trial of patients with relapsed/refractory multiple myeloma 
(RRMM). Methods: Patient-level EORTC QLQ-C30 and EORTC QLQ-MY20 data were 
collected in a clinical trial of RRMM patients (n= 640) and mapped to EQ-5D scores 
using published algorithms. Descriptive summaries of mapped EQ-5D scores were 
estimated overall, and treatment regimen by: health state (pre-progression, progres-
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improving quality of life over extending life. ConClusions: Advanced NSCLC is 
known to impact many domains of patients’ lives. This study demonstrates that 
emotional impact and time taken undergoing treatment may be undervalued by 
commonly employed HRQoL metrics in clinical trials. Future clinical trials of new 
lung cancer treatments should include assessment of these concepts. Ultimately, 
HRQoL instruments should be identified/developed that satisfactorily capture all 
factors deemed important by patients in order to fully reflect impact of new treat-
ments on patients’ lives.
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objeCtives: Differences in preferences for treatment outcomes are known to exist 
among patients and healthcare professionals, but rarely are data available that 
include the preferences of medical regulators. Methods: Discrete choice (DCE) 
methodology was applied via an online questionnaire among patients and experts 
(HCPs, European medical assessors) in three disease areas (atrial fibrillation (AF), 
breast cancer (BC) and type II diabetes (DB)) in the United Kingdom, France and 
the Netherlands. Selection of the attributes was made via focus group question-
naires among 150 patients in each disease area. Data for the required number of 
drug scenarios were compiled from existing medicines for the disease areas and 
participants were asked to choose the drug they preferred. An alternative-specific 
conditional logit model was used to evaluate the choices made for each pair of 
scenarios. Results: Data were collected from 1288 patients: 205 AF; 531 BC; 552 
DB. Data for HCPs and medical assessors present the expert view: 89 AF; 211 BC; 122 
DB. Atrial fibrillation patients chose the prevention of stroke as the most important 
attribute while for experts fatal bleeding was the most important attribute; all other 
attributes were given the same order of importance by both groups. For diabetes, 
both patients and experts indicated preventing cardiac disorders as most important 
attribute of a treatment. However, the order of the remaining attributes differed. For 
breast cancer, the order of importance of all the attributes was the same for patients 
and experts. The choices were not explained by demographic characteristics and 
disease severity had no impact on the choices made by patients. ConClusions: 
With the exception of breast cancer, the view that patients and experts have dif-
ferent preferences for treatment outcomes continues to be supported by this data. 
There may exist a chronic/acute illness axis that may differentiate the preferences 
between experts and patients.
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objeCtives: Recent initiatives within Europe to increase the involvement of 
patients in the regulation of medicines are positive actions. However, is there a 
shared view among European patients on the favorable and unfavorable outcomes 
of medicines? This study aims to assess differences in preferences for treatment 
outcomes across three countries in Europe. Methods: Data were collected via web-
questionnaires from patients diagnosed with atrial fibrillation (AF), breast cancer 
(BC) and type II diabetes (DB)) in the United Kingdom, France and the Netherlands. A 
panel of physicians, epidemiologists, and healthcare researchers reviewed favorable 
and unfavorable outcomes of current treatments and compiled a list of treatment 
outcomes. Patients were asked to rank by order of importance the treatment out-
comes specific to their area of disease. Results: A total of 454 patients provided 
data: age 20-75 years; predominantly female for DB and AF and all female for BC. 
AF patients across all countries ranked reduction in fatal ischemic stroke as the 
most favorable treatment outcome and fatal hemorrhage as the most unfavorable 
outcome. Dutch and British BC patients ranked overall survival as most favorable, 
while French BC patients selected health related quality of life. All BC patients 
selected cardiotoxicity as the most unfavorable outcome. Dutch and French DB 
patients ranked decreased fasting glucose as most favorable outcome, while British 
DB patients were divided between reduction in weight, reduction in hemoglobin and 
changes in blood pressure. Dutch and British DB patients ranked congestive heart 
failure as the most unfavorable outcome, while French patients selected hypogly-
cemia. ConClusions: Patient differences, as determined by demographics and 
disease characteristics, are commonplace in medical research; however exploration 
of country and regional differences in values and preferences among patients are 
less common and should be included in any research activity aimed at elucidating 
the representative patient voice for Europe.
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objeCtives: Novel treatments for advanced melanoma have been developed with dif-
fering levels of effectiveness, safety, cost, and route of administration. Understanding 
the preferences among these attributes between patients and physicians is necessary 
for quality treatment and shared decision making. In health care, Discrete Choice 
Experiment (DCE) is one of the recommended tools for eliciting treatment preferences 
by reflecting different perspectives and the trade-off between attributes. The objective 
of this study is to measure patient and physician preferences by conducting a DCE 
for advanced melanoma treatments with a special focus on immunotherapy and 
objeCtives: To determine the direct out-of-pocket expenses (co-payments) 
and overall satisfaction among patients enrolled in the Z Benefits for breast 
cancer. Methods: The database of paid claims was the sampling frame of the 
study. Participants were identified and trained data collectors conducted patient 
interviews using a pre-tested semi-structured survey tool. Participants signed an 
informed consent for an interview, audio and video documentation of feedbacks. 
Clinical data were extracted from medical records while out-of-pocket expenses 
were reviewed from statements of account and receipts of services received. 
Patient satisfaction during surgery, chemotherapy and overall patient satisfaction 
were validated with the satisfaction questionnaires submitted by the contracted 
hospitals. Results: A total of 80 claims for breast cancer using the Z benefit 
package were identified from July 2012 to August 2014 from five contracted hos-
pitals. Respondents underwent modified radical mastectomy with 50 patients 
receiving standard adjuvant chemotherapy. During hospital confinement, 41 
patients purchased medicines outside the hospital pharmacy. The overall aver-
age out-of-pocket expense was at Php 3600 (US$ 80). The average out-of-pocket 
expense was Php 4000 (US $ 89) for medicines, Php 1600 (US $ 36) for laboratory 
tests and Php 4200 (US $ 93) for professional fees which are within the allowed co-
payment limits. Patient satisfaction was generally good with satisfaction rates of 
98% and 92% for surgery and chemotherapy services, respectively. ConClusions: 
The overall patient satisfaction is favourable but there were still out-of-pocket 
expenses for medicines, laboratory tests and professional fees amounting to an 
average of Php 3,600 (US$80).
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objeCtives: To compare patient satisfaction with intravenous rituximab (RIV) 
versus subcutaneous rituximab (RSC) using the reliable and validated instrument, 
Rituximab Administration Satisfaction Questionnaire (RASQ). Methods: PrefMab 
(NCT01724021) is a randomized, open-label, crossover Phase IIIb study in patients 
with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma (grade 
1–3a). Patients received chemotherapy (6–8 cycles CHOP [cyclophosphamide, doxo-
rubicin, vincristine, prednisone], CVP [cyclophosphamide, vincristine, prednisone], 
or bendamustine) plus 8 cycles of rituximab; Arm A: 1 cycle RIV (375 mg/m2) and 
3 cycles RSC (1400 mg) then 4 cycles RIV; Arm B: 4 cycles RIV (375 mg/m2) then 
4 cycles RSC (1400 mg). The general Cancer Therapy Satisfaction Questionnaire 
(CTSQ), and RASQ, were conducted at cycles 4 and 8; domains for both question-
naires were scored 0 (least)–100 (best). Adverse events were monitored through-
out. Results: At the primary data cut, January 19, 2015, the intent-to-treat 
population was: Arm A, n= 372; Arm B, n= 371. Median age was 60 years (range 
18–80). Baseline characteristics were balanced between arms. Overall median 
CTSQ scores with RSC and RIV were similar for all domains: expectations, side 
effects, and satisfaction with therapy. Overall median RASQ scores were higher 
for RSC versus RIV for psychological impact (88 vs 80), impact on daily living (83 
vs 58), convenience (83 vs 58), and satisfaction with therapy (88 vs 75), with no 
difference for physical impact. Overall, most patients considered time required 
to administer R was ‘just right’ (88% SC vs 56% IV), and they had ’more than 
enough time’ to discuss concerns with their doctors/nurses (79% SC vs 79% IV). 
Treatment sequence did not impact CTSQ or RASQ scores. No new safety signals 
were detected. ConClusions: Patient satisfaction with R-chemotherapy was 
comparable for RSC and RIV. However, rituximab-specific satisfaction measured 
by RASQ was generally greater with RSC than RIV.
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objeCtives: The aim of this study was to better understand the impact of 
advanced NSCLC and its treatment on the quality of life and experience of 
patients, in order to inform the design and inclusion of outcome assessments in 
clinical trials. Methods: Face-to-face, qualitative, semi-structured interviews were 
conducted with 20 UK participants with advanced NSCLC. Interviews explored par-
ticipants’ experiences of aNSCLC and the treatment they received. Open-ended 
questioning (facilitating spontaneous reporting), was followed by focused questions 
to further investigate important themes. Creative methods including an impact rat-
ing ladder and timeline task were used to elicit content. Verbatim transcripts were 
analyzed using a data-driven, thematic analysis approach. Results: Participants 
experienced considerable burden from symptoms and treatment-related side effects 
(e.g. breathlessness, nausea), which left them unable to participate in activities 
of daily living such as housework, shopping or going outside. However, partici-
pants reported that the emotional impact on them and their families (e.g. worry, 
sadness and frustration) had the biggest negative impact on their lives. Almost 
all participants were highly satisfied with their treatment and care, but time lost 
to receiving and recovering from treatment was commonly reported. Efficiency, 
communication and practical and emotional support were aspects of care valued 
most by participants. The majority of participants asked said they would prioritise 
